Ado-trastuzumab emtansine 2023 medical insurance payment standards

Ado-trastuzumab emtansine) original drug has been launched in China and has entered the scope of medical insurance. Reimbursement is limited to eligible patients, including adjuvant treatment for patients with HER2-positive early breast cancer who still have invasive lesions after receiving neoadjuvant treatment based on taxanes combined with trastuzumab. Reimbursement is limited to patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who have received taxanes and trastuzumab.

Based on a trial, the U.S. Food and Drug Administration (FDA) approved trastuzumab for marketing on February 22, 2013, developed by Genentech and produced by Lonza. In the EMILIA clinical trial, women with HER2-positive advanced breast cancer who had developed resistance to trastuzumab alone had a median overall survival extension of 5.8 months compared with the combination of lapatinib and capecitabine (30.9 months vs. 25.1 months).

Enmei trastuzumab single-antigen drugs listed in the country are strictly controlled drugs, and the price of 100mg per box may be around 20,000 yuan. The reimbursement ratio is different in different regions, and the price after reimbursement may be different. For specific patients, please consult the local hospital or medical insurance bureau. Listed overseas Enmei Trastuzumab The single-unit generic drug has Turkish and European versions, with specifications The price of each box of 100 mg may be around 3,000-8,000 yuan (the price may fluctuate due to the exchange rate). The ingredients of the originator drugs sold domestically and abroad are basically the same, and there are currently no generic versions of Enmei Trastuzumab produced and launched.